|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||122.54 - 122.54|
|52-week range||122.54 - 122.54|
|Beta (5Y monthly)||1.94|
|PE ratio (TTM)||N/A|
|Earnings date||04 May 2021 - 10 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
n-Lorem Foundation Partners with Ultragenyx to Bolster Development of Personalized Medicines for Patients with Ultra-Rare Diseases
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The FDA clears Ultragenyx's (RARE) investigational new drug application for UX053 being developed to treat Glycogen Storage Disease Type III.